BioSpace News Archive

A study published in BMJ Open describes the Patient Journey as it relates to awareness, communication, and involvement with decision making during experiences with preeclampsia, a potentially life-threatening hypertensive disorder of pregnancy.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) announced today the launch of an Expanded Access Program (EAP) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in the U.S. for people living with amyotrophic lateral sclerosis (ALS) that meet program eligibility criteria.

Retinitis pigmentosa is a rare inherited disease that typically presents with loss of low light vision, followed by reduced visual field (loss of peripheral vision) and eventually loss of central vision.

Tampa General Hospital (TGH) and USF Health Morsani College of Medicine Interventional Cardiologists reached multiple milestones this week in being the first in Florida and second in the nation to use a newly developed heart implant designed to replace the tricuspid valve and offer an option to patients who do not meet the criteria for open heart surgery.

Physicians report that they need to devote as many as 10 additional hours per workweek to charting, much of which is after hours, based on an additional 5-10 minutes per chart and a 20 patient per day workload.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today reported unaudited financial results for the fourth quarter of 2021.

Viracta Therapeutics, Inc. today announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 200,000 shares of common stock.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Galapagos issued 95,500 new ordinary shares on 18 March 2022, for a total capital increase of €2,159,600.00.

BioLife Solutions, Inc. announced today that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).